Rabbit monoclonal antibody: Potential application in cancer therapy

American Journal of Translational Research

Volumn 3, Issue 3, 2011, Pages 269-274

  Feng, Lifeng ^a,b   Wang, Xian ^b   Jin, Hongchuan ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Cancer therapy; Monoclonal antibody; Rabbit monoclonal antibody

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; CETUXIMAB; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; NIMOTUZUMAB; OFATUMUMAB; PANITUMUMAB; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; TRASTUZUMAB;

ANTIBODY SPECIFICITY; BINDING AFFINITY; CANCER THERAPY; COST BENEFIT ANALYSIS; DRUG TARGETING; HUMAN; NONHUMAN; RABBIT; REVIEW; STRUCTURE ANALYSIS;

MURINAE; ORYCTOLAGUS CUNICULUS;

EID: 79957546696     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Kohler G and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497.
2. Reichert JM and Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007; 6: 349-356.
3. Reichert JM, Rosensweig CJ, Faden LB and Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23: 1073-1078.
4. Riechmann L, Clark M, Waldmann H and Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323-327.
5. Morrison SL, Johnson MJ, Herzenberg LA and Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A 1984; 81: 6851-6855.
6. Jones PT, Dear PH, Foote J, Neuberger MS and Winter G. Replacing the complementaritydetermining regions in a human antibody with those from a mouse. Nature 1986; 321: 522-525.
7. Ritter G, Cohen LS, Williams C, Jr., Richards EC, Old LJ and Welt S. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res 2001; 61: 6851-6859.
8. Hoda D, Simon GR and Garrett CR. Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab. Ther Clin Risk Manag 2008; 4: 1221-1227.
9. van Schouwenburg PA, Bartelds GM, Hart MH, Aarden L, Wolbink GJ and Wouters D. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. J Immunol Methods 2010; 362: 82-88.
10. Esquivel CO, Fung JJ, Markus B, Iwatsuki S, Gordon RD, Makowka L, Marsh JW, Jr., Tzakis AG, Todo S and Starzl TE. OKT3 in the reversal of acute hepatic allograft rejection. Transplant Proc 1987; 19: 2443-2446.
11. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T and Levy R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-2195.
12. Scott SD. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma. Cancer Pract 1998; 6: 195-197.
13. Oldham RK and Dillman RO. Monoclonal antibodies in cancer therapy: 25 years of progress. J Clin Oncol 2008; 26: 1774-1777.
14. Datamonitor. Monoclonal Antibodies: 2010.
15. Gerber DE. Targeted therapies: a new generation of cancer treatments. Am Fam Physician 2008; 77: 311-319.
16. Spieker-Polet H, Sethupathi P, Yam PC and Knight KL. Rabbit monoclonal antibodies: generating a fusion partner to produce rabbitrabbit hybridomas. Proc Natl Acad Sci U S A 1995; 92: 9348-9352.
17. Pytela R, Zhu, Weimin, Ke, Yaohuang, Qian, Qi, Au, Harry C. Fusion partner for production of monoclonal rabbit antibodies, Epitomics, Inc., United States: USP7429487. 2008.
18. Yu Y, Lee P, Ke Y, Zhang Y, Yu Q, Lee J, Li M, Song J, Chen J, Dai J, Do Couto FJ, An Z, Zhu W and Yu GL. A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models. PLoS One 2010; 5: e9072.
19. Bystryn JC, Jacobsen JS, Liu P and Heaney-Kieras J. Comparison of cell-surface human melanoma-associated antigens identified by rabbit and murine antibodies. Hybridoma 1982; 1: 465-472.
20. Raybould TJ and Takahashi M. Production of stable rabbit-mouse hybridomas that secrete rabbit mAb of defined specificity. Science 1988; 240: 1788-1790.
21. Schiaffella E, Sehgal D, Anderson AO and Mage RG. Gene conversion and hypermutation during diversification of VH sequences in developing splenic germinal centers of immunized rabbits. J Immunol 1999; 162: 3984-3995.
22. Knight KL and Crane MA. Generating the antibody repertoire in rabbit. Adv Immunol 1994; 56: 179-218.
23. An Z. Therapeutic Monoclonal Antibodies: From Bench to Clinic. Wiley, 2009.
24. Rossi S, Laurino L, Furlanetto A, Chinellato S, Orvieto E, Canal F, Facchetti F and Dei Tos AP. Rabbit monoclonal antibodies: a comparative study between a novel category of immunoreagents and the corresponding mouse monoclonal antibodies. Am J Clin Pathol 2005; 124: 295-302.
25. Welt S, Ritter G, Williams C, Jr., Cohen LS, John M, Jungbluth A, Richards EA, Old LJ and Kemeny NE. Phase I study of anticolon cancer humanized antibody A33. Clin Cancer Res 2003; 9: 1338-1346.
26. Couto F J R D, Hendricks, Kristin B., Wallace, Ellen S., Yu, Guo-liang. Methods for antibody engineering, Epitomics, Inc., United States: USP7462697.2008.
27. Powell WC, Hicks DG, Prescott N, Tarr SM, Laniauskas S, Williams T, Short S, Pettay J, Nagle RB, Dabbs DJ, Scott KM, Brown RW, Grogan T, Roche PC and Tubbs RR. A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility. Appl Immunohistochem Mol Morphol 2007; 15: 94-102.
28. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH and Weiss SW. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33: 459-465.